BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 31247693)

  • 1. [A Case of Late Onset Nivolumab-Induced Interstitial Nephritis in a Patient with Metastatic Renal Cell Carcinoma].
    Hattahara K; Yamasaki T; Sawada A; Tanigaki K; Endo S; Teramoto Y; Banno H; Fuchigami Y; Suzuki R; Fujiwara M; Hida T; Yoshino T; Kita Y; Goto T; Akamatsu S; Saito R; Kobayashi T; Inoue T; Ogawa O
    Hinyokika Kiyo; 2019 May; 65(5):157-161. PubMed ID: 31247693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A Case of Rheumatoid Arthritis Developed during Treatment with Nivolumab for Renal Cell Carcinoma].
    Tomizawa M; Nakai Y; Maesaka F; Owari T; Hara R; Miyake M; Inoue T; Anai S; Tanaka N; Fujimoto K
    Hinyokika Kiyo; 2018 Oct; 64(10):397-401. PubMed ID: 30543737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer.
    Nakatani Y; Kawakami H; Ichikawa M; Yamamoto S; Otsuka Y; Mashiko A; Takashima Y; Ito A; Nakagawa K; Arima S
    Invest New Drugs; 2018 Aug; 36(4):726-731. PubMed ID: 29623482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
    Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
    J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
    Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
    BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
    De Giorgi U; Cartenì G; Giannarelli D; Basso U; Galli L; Cortesi E; Caserta C; Pignata S; Sabbatini R; Bearz A; Buti S; Lo Re G; Berruti A; Bracarda S; Cognetti F; Rastelli F; Fornarini G; Porta C; Turci D; Sternberg CN; Procopio G;
    BJU Int; 2019 Jan; 123(1):98-105. PubMed ID: 29956884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute tubulointerstitial nephritis and IgM deposits on glomerular capillary walls after immunotherapy with nivolumab for metastatic renal cell carcinoma.
    Irifuku T; Satoh A; Tani H; Mandai K; Masaki T
    CEN Case Rep; 2020 Feb; 9(1):48-54. PubMed ID: 31605271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A Case of Nivolumab-Induced Isolated Adrenocorticotropic Hormone Deficiency Presenting Dyspnea].
    Ito K; Uchida T; Manabe Y; Miyazaki Y; Itoh H; Mishina M; Okuno H
    Hinyokika Kiyo; 2018 Oct; 64(10):391-395. PubMed ID: 30543736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case of complete response to neoadjuvant therapy using nivolumab in a patient with metastatic renal cell carcinoma.
    Ikarashi D; Kato Y; Katagiri H; Takahara T; Uesugi N; Shiomi E; Sugimura J; Nitta H; Sugai T; Obara W
    Int J Urol; 2018 Jun; 25(6):630-632. PubMed ID: 29693280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A CASE OF RENAL CELL CARCINOMA THAT ONCE NIVOLUMAB HAD BEEN EFFECTIVE IN METASTATIC LESION AND MADE PRIMARY TUMOR RESECTABLE].
    Tsukahara S; Nagatomi Y; Otsubo S; Hasegawa S
    Nihon Hinyokika Gakkai Zasshi; 2019; 110(1):32-35. PubMed ID: 31956216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report.
    Kopecký J; Kubeček O; Geryk T; Slováčková B; Hoffmann P; Žiaran M; Priester P
    J Med Case Rep; 2018 Sep; 12(1):262. PubMed ID: 30217214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Int J Clin Oncol; 2020 Apr; 25(4):705-712. PubMed ID: 31858306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
    Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
    J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial nephritis associated with nivolumab in a patient with hodgkin lymphoma.
    Oliveira DS; Mesquita JL; Garcia YDO; Rosales YMZ; Lemes RPG; Rocha Filho FD; Fernandes PFCBC; Duarte PMA; Pitombeira MDS; Duarte FB
    Rev Assoc Med Bras (1992); 2019 Aug; 65(7):934-936. PubMed ID: 31389500
    [No Abstract]   [Full Text] [Related]  

  • 15. Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.
    Huynh LM; Bonebrake BT; DiMaio DJ; Baine MJ; Teply BA
    Medicine (Baltimore); 2021 Dec; 100(49):e28199. PubMed ID: 34889301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Analysis of Renal Infiltrating Cells in Acute Tubulointerstitial Nephritis Induced by Anti-PD-1 Antibodies: A Case Report and Review of the Literature.
    Tabei A; Watanabe M; Ikeuchi H; Nakasatomi M; Sakairi T; Kaneko Y; Maeshima A; Kaira K; Hirato J; Nojima Y; Hiromura K
    Intern Med; 2018 Nov; 57(21):3135-3139. PubMed ID: 29877267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
    Yilmaz M
    J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eastern Spanish experience with nivolumab in metastatic renal cell carcinoma.
    José JM; Jose M; Silverio R; Federico V; Isabel C; Martin OA; Inmaculada B; Cristina C; Julia HC; Dolores TM; Jose G; Paola P; Nieves DP; Vicent A; Sara B; Sara M; Julián L; Manuel S; Del Carmen MM; Ángel CM; Vicente G
    Clin Transl Oncol; 2020 Sep; 22(9):1517-1523. PubMed ID: 32048159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatal hyperprogression induced by nivolumab in metastatic renal cell carcinoma with sarcomatoid features: a case report.
    Dionese M; Pierantoni F; Maruzzo M; Bimbatti D; Deppieri FM; Maran M; Gardiman MP; Basso U
    Anticancer Drugs; 2021 Feb; 32(2):222-225. PubMed ID: 32868643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab efficacy in leptomeningeal metastasis of renal cell carcinoma: a case report.
    Bonomi L; Bettini AC; Arnoldi E; Chirco A; Ghilardi L; Manara O; Roscigno M; Da Pozzo LF; Tondini CA
    Tumori; 2020 Dec; 106(6):NP76-NP78. PubMed ID: 32041500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.